Bridgebio Pharma, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
BridgeBio Pharma, Inc. has filed its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation proposals.
NASDAQ
DEFA14A: BridgeBio Pharma Seeks Stockholder Approval for Amended Stock Option Plan and Officer Exculpation
BridgeBio Pharma files a supplement to its proxy statement, seeking stockholder approval for an amended stock option plan and an officer exculpation provision at its upcoming annual meeting.
NASDAQ
BridgeBio Pharma, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.
NASDAQ
BridgeBio Pharma is holding its annual meeting on June 20, 2025, to vote on director elections, executive compensation, auditor ratification, and amendments to its stock option plan and corporate charter.
NASDAQ
BridgeBio Pharma has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
BridgeBio Pharma is asking stockholders to approve an amendment to its 2021 Stock Option and Incentive Plan, primarily to increase the number of shares available for issuance by 6,500,000.